AzurRx BioPharma, Inc.
AZRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $6 | $16 | $16 | $12 |
| - Cash | $3 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $1 | $0 |
| Enterprise Value | $4 | $17 | $17 | $12 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1 | -$1 | -$1 | -$4 |
| % Margin | – | – | – | – |
| Net Income | -$1 | -$1 | -$1 | $32 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.75 | -0.21 | -0.28 | -2.75 |
| % Growth | -257.1% | 25% | 89.8% | – |
| Operating Cash Flow | -$1 | -$0 | -$1 | $7 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1 | -$0 | -$1 | $7 |